The anti-inflammatory drug tocilizumab targets the IL-6 pathway to achieve a 54% remission rate in hard-to-treat depression.
Schematic diagram of the IL-6/JAK/STAT3 signaling pathway activation in mouse liver macrophages. IRs, inhibitory receptors (IRs); ICIs, immune checkpoint inhibitors; IL-6, interleukin-6; ALT, alanine ...
Schematic diagram of the IL-6/JAK/STAT3 signaling pathway activation in mouse liver macrophages. IRs, inhibitory receptors (IRs); ICIs, immune checkpoint inhibitors; IL-6, interleukin-6; ALT, alanine ...
Immunotherapy could be a promising new treatment option for patients with difficult-to-treat depression. This is a key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results